Lucia Bio
Lucia Bio is focused on the application of spleen tyrosine kinase (Syk) inhibitors in human immunology, with the first program developing a potential treatment for neuroinflammation associated with neurodegenerative conditions.
Syk inhibitors for neurodegenerative conditions
Lucia Bio, a collaboration between UniQuest and MTM is the first company in the Brisbane Pod. Lucia Bio is capitalising on QEDDI’s previous investment in the discovery of small molecule inhibitors of Syk, a critical node in many diseases of the human immune system.
Brain penetrant Syk inhibitor
The first program is the development of a brain penetrant oral small molecule, currently at candidate selection stage.
International project team
Experienced project team assembled with the goal of moving a Syk inhibitor into formal clinical development.
